A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

NCT02913313 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Broad Solid Tumor

Interventions

DRUG: BMS-986207
BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]